A pooled analysis of 4 MagnetisMM trials evaluated dosing strategies for elranatamab, a BCMA-CD3 bispecific antibody, to identify the optimal regimen that mitigates cytokine release syndrome in patients...
An open-label, randomized trial found that daratumumab and hyaluronidase-fihj administered subcutaneously improved the risk of disease progression or death in patients with multiple myeloma. As a result,...
A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
A phase 2 trial from the University of Miami evaluated whether combining iberdomide with carfilzomib, daratumumab, and dexamethasone could induce deep responses—including MRD-negativity—in patients with...
A phase 1b–2 trial published in The New England Journal of Medicine evaluated the combination of two bispecific antibodies, talquetamab and teclistamab, for patients with relapsed or refractory multiple...
For oncologists considering immunotherapy sequencing, a Nature report from MD Anderson Cancer Center in Houston, TX, suggests that receipt of a SARS-CoV-2 mRNA vaccine near the start of immune checkpoint...
A randomized clinical trial tested whether a digital health program delivered directly to patients could increase lung cancer screening rates among eligible adults. Conducted at two academic health systems,...
Stay up to date with the evolving standards of breast cancer care — our new timeline snapshot highlights the most significant U.S. clinical guideline changes from 2024 to present, including updates from...
A phase 2 nonrandomized clinical trial explored whether breast surgery could be safely eliminated for women with ERBB2-positive or triple-negative invasive breast cancer who achieved a pathologic complete...
